Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines

Journal of Neurosurgery

Volumn 103, Issue 1, 2005, Pages 156-164

  Kjaergaard, Jorgen ^a   Wang, Li Xin ^a   Kuriyama, Hideyuki ^a   Shu, Suyu ^a   Plautz, Gregory E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cell; Electrofusion; Glioma; Immunotherapy; Mouse; Tumor model

Indexed keywords

DENDRITIC CELL VACCINE; TUMOR CELL VACCINE; VACCINE; CANCER VACCINE; CD134 ANTIGEN; TNFRSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ACTIVE IMMUNIZATION; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DENDRITIC CELL; ELECTROFUSION (CELL); FEMALE; FIBROSARCOMA; GLIOMA; HETEROKARYON; INTRACRANIAL TUMOR; LYMPHOCYTIC INFILTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR REGRESSION; VACCINATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CELL FUSION; DISEASE MODEL; DRUG ANTAGONISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CELL FUSION; CHEMOTHERAPY, ADJUVANT; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; FIBROSARCOMA; GLIOMA; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; RADIOTHERAPY, ADJUVANT; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 24944552128     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2005.103.1.0156     Document Type: Article

References (57)

1. Akasaki Y, Kikuchi T, Homma S, Abe T, Kufe D, Ohno T: Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106-113, 2001
2. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177-1182, 1997
3. Ausman JI, Shapiro WR, Rall DP: Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30:2394-2400, 1970
4. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392:245-252, 1998
5. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12:1539-1546, 2000
6. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, et al: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21:3826-3835, 2003
7. Billingham RE, Brent L, Medawar PW: Quantitative studies on tissue transplantation immunity. II, the origin, strength and duration of actively and adoptively acquired immunity. Proc Roy Soc Biol 143:58-80, 1954
8. Calzascia T, Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, et al: Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 171:2187-2191, 2003
9. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997
10. Conrad C, Nestle FO: Dendritic cell-based cancer therapy. Curr Opin Mol Ther 5:405-412, 2003
11. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol 30 (Suppl 8):23-29, 2003
12. Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, et al: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol 64:161-176, 2003
13. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273, 2000
14. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L: Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 14:833-843, 2003
15. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ: Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62:1462-1470, 2002
16. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, et al: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14-20, 2002
17. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD: Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 18:530-536, 2003
18. Huettner C, Paulus W, Roggendorf W: Messenger RNA expression of the immunosuppressive cytokine Il-10 in human gliomas. Am J Path 146:317-322, 1995
19. Inoue M, Plautz GE, Shu S: Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 56:4702-4708, 1996
20. Jelsma R, Bucy PC: The treatment of glioblastoma multiforme of the brain. J Neurosurg 27:388-400, 1967
21. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337-344, 2001
22. Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinbert AD, Shu S: Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 167:6669-6677, 2001
23. Kjaergaard J, Peng L, Cohen PA, Shu S: Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol 108:8-20, 2003
24. Kjaergaard J, Shimizu K, Shu S: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225:65-74, 2003
25. Lambert LA, Gibson GR, Maloney M, Barth RJ Jr: Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 24:232-236, 2001
26. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr: Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61:641-646, 2001
27. Liau LM, Black KL, Prins RM, Sykes SN, DiPatra PL, Cloughesy TF, et al: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115-1124, 1999
28. Maxwell M, Galanpoulos T, Neville-Golden J, Antoniades HN: Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76:799-804, 1992
29. Medzhitov R, Janeway CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295-298, 1997
30. Mukai S, Kjaergaard J, Shu S, Plautz GE: Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 59:5245-5249, 1999
31. Neil GA, Zimmermann U: Electrofusion. Methods Enzymol 220:174-196, 1993
32. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
33. North RJ: Gamma-radiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16:175-181, 1984
34. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, et al: Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196-201, 1998
35. Okano F, Storkus WJ, Chambers WH, Pollac IF, Okada H: Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851-2855, 2002
36. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317-5325, 2003
37. Perrin G, Schnuriger V, Quiquerez AL, Saas P, Pannetier C, de Tribolet N, et al: Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11:1337-1350, 1999
38. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89:42-51, 1998
39. Plautz GE, Inoue M, Shu S: Defining the synergistic effects of radiation and T-cell immunotherapy for murine intracranial tumors. Cell Immunol 171:277-284, 1996
40. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209-2218, 2000
41. Plautz GE, Mukai S, Cohen PA, Shu S: Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 165:3656-3662, 2000
42. Plautz GE, Touhalisky JE, Shu S: Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 178:101-107, 1997
43. Prins RM, Graf MR, Merchant RE, Black KL, Wheeler CJ: Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression. J Neurooncol 64:45-54, 2003
44. Prins RM, Odesa SK, Liau LM: Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487-8491, 2003
45. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335-341, 1999
46. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147, 2003
47. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, et al: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918-4923, 2003
48. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265-272, 2004
49. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
50. Struss AK, Romeike BF, Munnia A, Nastainczyk W, Steudel WI, Konig J, et al: PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 20:4107-4114, 2001
51. Tanaka H, Shimizu K, Hayashi T, Shu S: Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220:1-12, 2002
52. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343, 1978
53. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303:1323-1329, 1980
54. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE: Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 172:3462-3468, 2004
55. Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, et al: Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171:4927-4933, 2003
56. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-737, 1991
57. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001